{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:12Z","timestamp":1788901992799,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cca.2026.121190","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:42:44Z","timestamp":1781851364000},"page":"121190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["BCL-2 in leukemia: Enhancing clinical utility"],"prefix":"10.1016","volume":"592","author":[{"given":"Zia Ur","family":"Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abida","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Azhar","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Imtiaz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Afroz","family":"Bakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121190_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-017-0359-0","article-title":"The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia","volume":"12","author":"Lampson","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0025","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/ijms25031421","article-title":"Biomarkers of response to venetoclax therapy in acute myeloid leukemia","volume":"25","author":"Rodr\u00edguez-Medina","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121190_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1501950","article-title":"BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies","volume":"14","author":"Markouli","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121190_bb0035","series-title":"StatPearls","article-title":"Laboratory Evaluation of Acute Leukemia","author":"Tripathi","year":"2026"},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0040","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3390\/cancers13122974","article-title":"Potential biomarkers for treatment response to the BCL-2 inhibitor venetoclax: state of the art and future directions","volume":"13","author":"Salah","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01757343","article-title":"High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis","volume":"69","author":"Gala","year":"1994","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.cca.2026.121190_bb0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X","article-title":"The Bax\u03b1:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia","volume":"71","author":"Salomons","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0055","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"issue":"9\u201310","key":"10.1016\/j.cca.2026.121190_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2119\/2008.00061.McCarthy","article-title":"Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18)","volume":"14","author":"McCarthy","year":"2008","journal-title":"Mol. Med."},{"issue":"21","key":"10.1016\/j.cca.2026.121190_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215096","article-title":"BCL-2 expression in AML patients over 65 years: impact on outcomes across different therapeutic strategies","volume":"10","author":"Tiribelli","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.121190_bb0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood.V81.4.1025.1025","article-title":"Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein","volume":"81","author":"Campana","year":"1993","journal-title":"Blood"},{"issue":"5303","key":"10.1016\/j.cca.2026.121190_bb0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","article-title":"Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked","volume":"275","author":"Yang","year":"1997","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cca.2026.121190_bb0080","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/blood.V89.8.2986","article-title":"Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia","volume":"89","author":"Findley","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2004.07.011","article-title":"Antiapoptotic BCL-2 is required for maintenance of a model leukemia","volume":"6","author":"Letai","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/leu.2013.361","article-title":"Differential expression of miR-17\u223c92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia","volume":"28","author":"Scherr","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121190_bb0095","doi-asserted-by":"crossref","DOI":"10.1590\/S0100-879X2006000300003","article-title":"Fludarabine induces apoptosis in chronic lymphocytic leukemia: the role of P53, Bcl-2, Bax, mcl-1, and Bag-1 proteins","volume":"39","author":"Faria","year":"2006","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"18","key":"10.1016\/j.cca.2026.121190_bb0100","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1182\/blood-2013-08-519470","article-title":"Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity","volume":"123","author":"Rooswinkel","year":"2014","journal-title":"Blood"},{"issue":"413","key":"10.1016\/j.cca.2026.121190_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1214","article-title":"Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways","volume":"9","author":"Saito","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2478\/raon-2023-0017","article-title":"The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients","volume":"57","author":"Pravdic","year":"2023","journal-title":"Radiol. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2026.121190_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47050346","article-title":"The role of BCL-2 expression in patients with myelodysplastic neoplasms","volume":"47","author":"Kuszczak","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2004.05155.x","article-title":"Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors","volume":"127","author":"Hartung","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cyto.b.20623","article-title":"ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones","volume":"82B","author":"Craig","year":"2012","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.cca.2026.121190_bb0130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2018.00683","article-title":"Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective","volume":"9","author":"Darwiche","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121190_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101195","article-title":"BCL-2 inhibition in haematological malignancies: clinical application and complications","volume":"65","author":"Fowler-Shorten","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.cca.2026.121190_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662866","article-title":"Of lymph nodes and CLL cells: deciphering the role of CCR7 in the pathogenesis of CLL and understanding its potential as therapeutic target","volume":"12","author":"Cuesta-Mateos","year":"2021","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.cca.2026.121190_bb0145","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2026.121190_bb0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cyto.b.21090","article-title":"Bcl-2 level as a biomarker for 13q14 deletion in CLL","volume":"84B","author":"Degheidy","year":"2013","journal-title":"Cytometry B Clin. Cytom."},{"issue":"7","key":"10.1016\/j.cca.2026.121190_bb0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2014.116707","article-title":"Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia","volume":"100","author":"Karawajew","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0160","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/sj.leu.2400854","article-title":"High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cca.2026.121190_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103090","article-title":"Absence of BCL-2 expression identifies a subgroup of AML with distinct phenotypic, molecular, and clinical characteristics","volume":"9","author":"Haes","year":"2020","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0170","article-title":"BCL2 expression at post-induction and complete remission impact outcome in acute myeloid leukemia","volume":"10","author":"Bilbao-Sieyro","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0175","doi-asserted-by":"crossref","first-page":"38354","DOI":"10.1038\/s41598-025-22331-5","article-title":"Decreased expression of BCL2 protein on the diagnostic bone marrow T cells in adult acute myeloid leukemia","volume":"15","author":"Shi","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0180","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140","article-title":"Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia","volume":"87","author":"Coustan-Smith","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/08880019809167229","article-title":"BCL-2 expression and prognosis in childhood acute leukemia","volume":"15","author":"Tsurusawa","year":"1998","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.cca.2026.121190_bb0190","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.leu.2401529","article-title":"Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome","volume":"13","author":"Salomons","year":"1999","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cca.2026.121190_bb0195","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.leu.2401866","article-title":"Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax\/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo","volume":"14","author":"Prokop","year":"2000","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0200","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0b013e318286d29b","article-title":"The BCL-2 protein in precursor B acute lymphoblastic leukemia in children","volume":"35","author":"Chaber","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121190_bb0205","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/bjc.1997.487","article-title":"Bcl-2\/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance","volume":"76","author":"Pepper","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2015.131854","article-title":"Clinical significance of bax\/bcl-2 ratio in chronic lymphocytic leukemia","volume":"101","author":"Del Principe","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2006-03-009670","article-title":"Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus","volume":"109","author":"Souabni","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2026.121190_bb0220","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3109\/10428190903207530","article-title":"BCL2-938C>a polymorphism and disease progression in chronic lymphocytic leukemia","volume":"50","author":"Zenz","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.cca.2026.121190_bb0225","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Pepper","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2026.121190_bb0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.cca.2026.121190_bb0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cca.2026.121190_bb0240","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0245","first-page":"403","article-title":"Bcl-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis","volume":"6","author":"Ahmed","year":"1999","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0250","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2005-07-2930","article-title":"The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia","volume":"107","author":"Holleman","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cca.2026.121190_bb0255","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/pbc.24518","article-title":"BAX\/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia","volume":"60","author":"Sharawat","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.cca.2026.121190_bb0260","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.31557\/APJCP.2022.23.5.1679","article-title":"Relationship between Bax and Bcl-2 protein expression and outcome of induction phase chemotherapy in pediatric acute lymphoblastic leukemia","volume":"23","author":"Cahyadi","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.cca.2026.121190_bb0270","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.cca.2026.121190_bb0275","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.cca.2026.121190_bb0280","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cca.2026.121190_bb0290","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2016.345","article-title":"Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis","volume":"31","author":"Thol","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.cca.2026.121190_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.cca.2026.121190_bb0300","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.cca.2026.121190_bb0305","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","article-title":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cca.2026.121190_bb0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.cca.2026.121190_bb0320","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.cca.2026.121190_bb0325","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-024-06864-7","article-title":"Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation","volume":"15","author":"Enzenm\u00fcller","year":"2024","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.cca.2026.121190_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cyto.b.21383","article-title":"Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors","volume":"92","author":"Smith","year":"2017","journal-title":"Cytometry B Clin. Cytom."},{"issue":"9","key":"10.1016\/j.cca.2026.121190_bb0335","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2004-01-0243","article-title":"BCL2 protein expression parallels its mRNA level in normal and malignant B cells","volume":"104","author":"Shen","year":"2004","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.cca.2026.121190_bb0340","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/10428199809058365","article-title":"BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine","volume":"28","author":"Zaja","year":"1998","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17122045","article-title":"An update on flow cytometry analysis of hematological malignancies: focus on standardization","volume":"17","author":"Holl","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0350","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/17474086.2024.2429604","article-title":"BCL-2 inhibition in acute myeloid leukemia: resistance and combinations","volume":"17","author":"Tatarata","year":"2024","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0355","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02260-7","article-title":"BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia","volume":"24","author":"Chong","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.121190_bb0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.121190_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087180","article-title":"Synergistic action of MCL-1 inhibitor with BCL-2\/BCL-XL or MAPK pathway inhibitors enhances acute myeloid leukemia cell apoptosis and differentiation","volume":"24","author":"Opydo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.cca.2026.121190_bb0370","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/bloodadvances.2022007728","article-title":"BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia","volume":"7","author":"Olesinski","year":"2023","journal-title":"Blood Adv."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:53:17Z","timestamp":1788900797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":74,"alternative-id":["S0009898126003724"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121190","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCL-2 in leukemia: Enhancing clinical utility","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121190"}}